Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 10:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 270 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Herpes Simplex Virus Infection Clear all
Completed Phase 1 Interventional

A Phase I/II Study of the Safety and Efficacy of Topical 1-(S)-(3-Hydroxy-2-Phosphonylmethoxypropyl)Cytosine Dihydrate (Cidofovir; HPMPC) in the Treatment of Refractory Mucocutaneous Herpes Simplex Disease in Patients With AIDS

NCT00002116
View directory record Official record
Conditions
Herpes Simplex, HIV Infections
Interventions
Cidofovir
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
13 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
8
States / cities
Los Angeles, California • San Francisco, California • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 9, 2026, 10:30 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

A Study That Collects Participant Data and Biospecimens to Analyze Pathogenic Exosomes That Mediate Increased Vascular Dementia Risk in Individuals With Herpes Zoster.

NCT06903078
View directory record Official record
Conditions
Herpes Zoster (HZ), Vascular Dementia
Interventions
Not listed
Lead sponsor
Center for Clinical Studies, Texas
Other
Eligibility
18 Years and older
Enrollment
375 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2030
U.S. locations
2
States / cities
Houston, Texas • Webster, Texas
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Oct 9, 2026, 10:30 AM EDT
Completed Phase 3 Interventional

Comparison of Foscarnet Versus Vidarabine in the Treatment of Herpes Infection in Patients With AIDS Who Have Not Had Success With Acyclovir

NCT00000985
View directory record Official record
Conditions
Herpes Simplex, HIV Infections
Interventions
Vidarabine, Acyclovir, Foscarnet sodium
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1990
U.S. locations
4
States / cities
Chicago, Illinois • Boston, Massachusetts • Rochester, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 9, 2026, 10:30 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Consistency, Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults ≥ 50 Years of Age

NCT02075515
View directory record Official record
Conditions
Herpes Zoster, Herpes Zoster Vaccine
Interventions
Herpes Zoster vaccine (GSK 1437173A)
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older
Enrollment
651 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
3
States / cities
Mesa, Arizona • Wichita, Kansas • Milford, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 14, 2021 · Synced Oct 9, 2026, 10:30 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Posoleucel (ALVR105, Formerly Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant

NCT04693637
View directory record Official record
Conditions
Adenovirus Infection, BK Virus Infection, Cytomegalovirus Infections, Epstein-Barr Virus Infections, Human Herpes Virus-6 Infection, JC Virus Infection
Interventions
Posoleucel (ALVR105)
Biological
Lead sponsor
AlloVir
Industry
Eligibility
1 Year and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
16
States / cities
Birmingham, Alabama • Duarte, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated May 9, 2024 · Synced Oct 9, 2026, 10:30 AM EDT
Terminated Phase 4 Interventional Results available

Effect of HSV-2 Suppressive Therapy on Sexual Behavior

NCT00495716
View directory record Official record
Conditions
Genital Herpes
Interventions
acyclovir
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 7, 2023 · Synced Oct 9, 2026, 10:30 AM EDT
Completed Phase 4 Interventional Results available

A Randomized Trial to Evaluated the Suppressive Effect of Acyclovir on Rapidly Cleared HSV-2 Reactivation

NCT00723229
View directory record Official record
Conditions
Genital Herpes
Interventions
acyclovir
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 9, 2017 · Synced Oct 9, 2026, 10:30 AM EDT
Withdrawn Phase 2Phase 3 Interventional

Antiviral Prophylaxis in a Burn Population

NCT02349828
View directory record Official record
Conditions
Herpes Simplex
Interventions
Acyclovir
Drug
Lead sponsor
Southern Illinois University
Other
Eligibility
24 Months and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Springfield, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 21, 2016 · Synced Oct 9, 2026, 10:30 AM EDT
Completed Phase 2 Interventional

Dextromethorphan Versus Placebo for Neuropathic Pain

NCT00001344
View directory record Official record
Conditions
Diabetic Neuropathies, Herpes Zoster, Neuralgia
Interventions
dextromethorphan
Drug
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
Not listed
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 9, 2026, 10:30 AM EDT
Not listed No phase listed Observational

Treating Genital Herpes Infection to Reduce Racial Disparities in the Risk of Severe Maternal Morbidity

NCT05429346
View directory record Official record
Conditions
Genital Herpes Simplex, Maternal Morbidity, Racial Disparities
Interventions
Not listed
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
339,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Oct 9, 2026, 10:30 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Optimization of the ex Vivo Challenge: Reproductive Infections and Contraception

NCT02375425
View directory record Official record
Conditions
HIV
Interventions
no intervention
Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
294 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 24, 2018 · Synced Oct 9, 2026, 10:30 AM EDT
Not yet recruiting Phase 2 Interventional

Evaluating Benzoyl Peroxide for Preventing Recurrence of HSV-1 Outbreaks With Rescue Crossover Option

NCT07032649
View directory record Official record
Conditions
HSV
Interventions
Benzoyl Peroxide 10% Bar, Placebo
Drug · Other
Lead sponsor
Greg Bew
Industry
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Evans, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 5, 2025 · Synced Oct 9, 2026, 10:30 AM EDT
Completed Phase 4 Interventional

A Study of Valacyclovir to Suppress HSV and HIV Shedding in Coinfected Persons

NCT00161434
View directory record Official record
Conditions
Herpes Simplex, HIV Infections
Interventions
valacyclovir, placebo
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 10, 2008 · Synced Oct 9, 2026, 10:30 AM EDT
Terminated Phase 3 Interventional

A Comparative Study of FV-100 vs. Valacyclovir for the Prevention of Post-Herpetic Neuralgia

NCT02412917
View directory record Official record
Conditions
Shingles, Herpes Zoster, Postherpetic Neuralgia
Interventions
FV-100, valacyclovir
Drug
Lead sponsor
ContraVir Pharmaceuticals, Inc.
Industry
Eligibility
30 Years and older
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Webster, Texas
Source: ClinicalTrials.gov public record
Updated Dec 22, 2017 · Synced Oct 9, 2026, 10:30 AM EDT
Completed No phase listed Observational

A Two Arm, Multi-Site Clinical Evaluation of the ARIES HSV 1&2 Assay in Symptomatic Patients

NCT02092233
View directory record Official record
Conditions
Herpes
Interventions
Not listed
Lead sponsor
Luminex Corporation
Industry
Eligibility
Not listed
Enrollment
1,963 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
3
States / cities
Springfield, Massachusetts • Albuquerque, New Mexico • Burlington, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 10, 2015 · Synced Oct 9, 2026, 10:30 AM EDT
Completed Phase 2 Interventional

Efficacy and Safety of Acyclovir-penciclovir Cream Versus an Abreva in the Suppression of Herpes Simplex Virus Eruptions

NCT06558838
View directory record Official record
Conditions
Herpes Simplex Oral
Interventions
acyclovir-penciclovir cream, Abreva
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Murray, Utah
Source: ClinicalTrials.gov public record
Updated Jan 5, 2026 · Synced Oct 9, 2026, 10:30 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Use of an Electronic Medical Record in the Primary Care Setting to Improve Herpes Zoster Vaccination Rates

NCT01519570
View directory record Official record
Conditions
Herpes Zoster Disease
Interventions
An informational packet regarding shingles and the HZV was sent to patients identified by the EMR
Other
Lead sponsor
Ohio State University
Other
Eligibility
60 Years and older
Enrollment
2,589 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 1, 2019 · Synced Oct 9, 2026, 10:30 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study on the Immune Response and Safety of the Shingles Vaccine and the Influenza Vaccine When Either is Given to Healthy Adults at the Same Time or Following a COVID-19 Booster Vaccine

NCT05047770
View directory record Official record
Conditions
Herpes Zoster
Interventions
HZ/su, Flu D-QIV, mRNA-1273
Biological · Combination Product
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
2,013 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
46
States / cities
Tempe, Arizona • Oxnard, California • San Diego, California + 40 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2023 · Synced Oct 9, 2026, 10:30 AM EDT
Completed Phase 2 Interventional

The Immunogenicity and Safety of Zostavax® and Shingrix® in Rheumatoid Arthritis Patients Using Abatacept

NCT03604406
View directory record Official record
Conditions
Herpes Zoster, Inflammatory Disease, Rheumatoid Arthritis
Interventions
Varicella Zoster Vaccine, Placebo Injection
Biological · Other
Lead sponsor
Kevin Winthrop
Other
Eligibility
18 Years and older
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
5
States / cities
Boise, Idaho • Eagan, Minnesota • Clovis, New Mexico + 2 more
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 9, 2026, 10:30 AM EDT
Withdrawn No phase listed Observational

NOWDx Test for the Diagnosis of Herpes Simplex Virus Type 2

NCT04294030
View directory record Official record
Conditions
HSV-2 Infection, Herpes Simplex Virus Infection
Interventions
Diagnostic Test: NOWDx HSV-2 Test
Device
Lead sponsor
NOWDiagnostics, Inc.
Industry
Eligibility
18 Years to 64 Years
Timeline
2023
U.S. locations
3
States / cities
Tempe, Arizona • Coral Gables, Florida • Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Feb 29, 2024 · Synced Oct 9, 2026, 10:30 AM EDT
Completed No phase listed Observational

Seroprevalence of Kaposi's Sarcoma Herpes Virus in the United States

NCT00026728
View directory record Official record
Conditions
Kaposi's Sarcoma, Herpesviridae Infection
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
20,169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 9, 2026, 10:30 AM EDT
Completed No phase listed Observational

Long-term Follow-up of GEN-003-002 Subjects for Efficacy and Immunogenicity

NCT02910284
View directory record Official record
Conditions
Genital Herpes Simplex Type 2
Interventions
Observational
Biological
Lead sponsor
Genocea Biosciences, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
13
States / cities
Birmingham, Alabama • San Diego, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2017 · Synced Oct 9, 2026, 10:30 AM EDT
Completed Phase 3 Interventional Results available

Phase 3 Clinical Study for the Treatment of Cold Sore

NCT00769314
View directory record Official record
Conditions
Herpes Labialis
Interventions
Acyclovir Lauriad, Placebo
Drug
Lead sponsor
Valerio Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
1,727 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
10
States / cities
Scottsdale, Arizona • Tucson, Arizona • San Francisco, California + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2012 · Synced Oct 9, 2026, 10:30 AM EDT
Completed Phase 3 Interventional

Long-Term Oral Acyclovir Usage to Prevent Herpes Zoster Virus Infection After Bone Marrow Transplant

NCT00209352
View directory record Official record
Conditions
VZV Infection After Bone Marrow Transplantation
Interventions
Acyclovir
Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
10 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1985 – 2004
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 21, 2007 · Synced Oct 9, 2026, 10:30 AM EDT